CO6361953A2 - Fusiones y conjugados de fármaco - Google Patents

Fusiones y conjugados de fármaco

Info

Publication number
CO6361953A2
CO6361953A2 CO11124244A CO11124244A CO6361953A2 CO 6361953 A2 CO6361953 A2 CO 6361953A2 CO 11124244 A CO11124244 A CO 11124244A CO 11124244 A CO11124244 A CO 11124244A CO 6361953 A2 CO6361953 A2 CO 6361953A2
Authority
CO
Colombia
Prior art keywords
fusions
drug
conjugates
relates
glp
Prior art date
Application number
CO11124244A
Other languages
English (en)
Inventor
Christopher Herring
Lucy J Holt
Malgorzada Pupeka
Sebastian Mayer
Laurent S Jespers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42308293&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6361953(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO6361953A2 publication Critical patent/CO6361953A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a fusiones de fármaco que tienen semividas en suero mejoradas. Estas fusiones y conjugados comprenden polipéptidos, dominios variables únicos de inmunoglobulina (anticuerpos) y moléculas de GLP y/o exendina. La invención se refiere además a usos, formulaciones, composiciones y dispositivos que comprenden tales fusiones y conjugados de fármaco.
CO11124244A 2009-03-27 2011-09-22 Fusiones y conjugados de fármaco CO6361953A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16391709P 2009-03-27 2009-03-27

Publications (1)

Publication Number Publication Date
CO6361953A2 true CO6361953A2 (es) 2012-01-20

Family

ID=42308293

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11124244A CO6361953A2 (es) 2009-03-27 2011-09-22 Fusiones y conjugados de fármaco

Country Status (24)

Country Link
US (2) US8779103B2 (es)
EP (1) EP2411054A2 (es)
JP (1) JP2012521971A (es)
KR (1) KR20110137819A (es)
CN (2) CN102481373A (es)
AR (1) AR076147A1 (es)
AU (1) AU2010227552B2 (es)
BR (1) BRPI1013588A2 (es)
CA (1) CA2756853A1 (es)
CL (1) CL2011002387A1 (es)
CO (1) CO6361953A2 (es)
DO (1) DOP2011000288A (es)
EA (1) EA021146B1 (es)
IL (1) IL215200A0 (es)
MA (1) MA33221B1 (es)
MX (1) MX2011010151A (es)
NZ (1) NZ595344A (es)
PE (1) PE20120514A1 (es)
SG (1) SG174497A1 (es)
TW (1) TW201100104A (es)
UA (1) UA98911C2 (es)
UY (1) UY32514A (es)
WO (1) WO2010108937A2 (es)
ZA (1) ZA201107022B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021146B1 (ru) * 2009-03-27 2015-04-30 Глаксо Груп Лимитед Продукты слияния и конъюгаты лекарственных средств
CN102666586A (zh) * 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
EA201291009A1 (ru) * 2010-05-20 2013-05-30 Глаксо Груп Лимитед Улучшенные связывающие варианты против сывороточного альбумина
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
WO2012136790A1 (en) * 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
IL293155A (en) 2011-06-23 2022-07-01 Ablynx Nv Techniques for predicting, detecting, and reducing A-specific protein interference in assays involving single immunoglobulin variable domains
LT2723771T (lt) * 2011-06-23 2019-12-10 Ablynx Nv Serumo albuminą surišantys baltymai
CN102949730A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 特异结合glp-1受体的药物融合体
CN102949731A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 与glp-2受体特异性结合的药物融合体
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN102827277B (zh) * 2012-04-26 2014-12-10 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其碳端连接多肽药物的方法
CN102875675B (zh) * 2012-04-26 2015-05-27 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其氮端连接多肽药物的方法
TW201514193A (zh) * 2013-01-31 2015-04-16 Glaxo Group Ltd 製備蛋白質之方法
BR112016016578A2 (pt) 2014-01-20 2017-10-03 Hanmi Pharm Ind Co Ltd Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma
RU2016137264A (ru) * 2014-02-21 2018-03-26 МЕДИММЬЮН, ЭлЭлСи Слияния антитела к pcsk9~glp-1 и способы применения
SG10201805288QA (en) 2014-05-16 2018-07-30 Ablynx Nv Improved immunoglobulin variable domains
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
CA2957354A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
SG11201810256XA (en) * 2016-05-18 2018-12-28 Modernatx Inc Polynucleotides encoding relaxin
TWI774694B (zh) 2016-09-23 2022-08-21 南韓商韓美藥品股份有限公司 具有降低對胰島素受體之親和力之胰島素類似物及其用途
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽－1及其修饰物的应用
BR112019019823A2 (pt) 2017-03-23 2020-04-22 Hanmi Pharm Ind Co Ltd conjugado, composição farmacêutica para prevenir ou tratar diabetes e método para tratamento de diabetes
TWI810937B (zh) 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI809515B (zh) 2017-12-21 2023-07-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
EP3810186B1 (en) 2018-06-21 2022-09-28 Novo Nordisk A/S Novel compounds for treatment of obesity
CN111234015B (zh) * 2020-02-12 2021-04-06 康维众和(中山)生物药业有限公司 用于延长药物半衰期的抗体、其融合蛋白和应用
EP4119571A4 (en) * 2020-03-12 2024-04-03 Sl Metagen NEW BISPECIFIC PROTEIN AND USE THEREOF
WO2022015039A1 (ko) * 2020-07-14 2022-01-20 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
EP0464022B1 (en) 1989-03-20 2000-05-31 The General Hospital Corporation Insulinotropic hormone
DK0512042T3 (da) 1990-01-24 1998-05-11 Douglas I Buckley GLP-1-analoger anvendelige ved diabetesbehandling
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
ES2294427T3 (es) 1997-07-07 2008-04-01 Medical Research Council Procedimiento para aumentar la concentracion de una molecula de acido nucleico.
EP1019077B2 (en) 1997-08-08 2010-12-22 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
EP1032587B2 (en) 1997-11-14 2013-03-13 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU757748B2 (en) 1997-11-14 2003-03-06 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
DE69936446T2 (de) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego Inotropische und diuretische effekte von exendin und glp-1
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
EA005584B1 (ru) 2000-12-07 2005-04-28 Эли Лилли Энд Компани Слитые белки glp-1
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
KR20120133403A (ko) * 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
US20060052301A1 (en) 2004-06-03 2006-03-09 Ronen Shemesh Splice variants of peptide YY, neuropeptide Y, pancreatic peptide Y and Amylin, and uses thereof
EP2769990A3 (en) 2004-12-02 2015-02-25 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
US20110020345A1 (en) * 2008-03-31 2011-01-27 Christopher Herring Drug fusions and conjugates
EA028178B1 (ru) * 2009-02-19 2017-10-31 Глэксо Груп Лимитед Улучшенные связывающие сывороточный альбумин варианты
SG173488A1 (en) * 2009-02-19 2011-09-29 Glaxo Group Ltd Improved anti-serum albumin binding variants
EA021146B1 (ru) * 2009-03-27 2015-04-30 Глаксо Груп Лимитед Продукты слияния и конъюгаты лекарственных средств
CN102666586A (zh) * 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物

Also Published As

Publication number Publication date
NZ595344A (en) 2013-09-27
CL2011002387A1 (es) 2012-07-20
EA201190184A1 (ru) 2012-05-30
EA021146B1 (ru) 2015-04-30
US20140193407A1 (en) 2014-07-10
CA2756853A1 (en) 2010-09-30
MA33221B1 (fr) 2012-04-02
UA98911C2 (uk) 2012-06-25
KR20110137819A (ko) 2011-12-23
US8779103B2 (en) 2014-07-15
US20120100141A1 (en) 2012-04-26
WO2010108937A2 (en) 2010-09-30
AR076147A1 (es) 2011-05-18
BRPI1013588A2 (pt) 2016-04-19
AU2010227552A1 (en) 2011-11-03
AU2010227552B2 (en) 2015-02-26
IL215200A0 (en) 2011-12-29
PE20120514A1 (es) 2012-05-14
JP2012521971A (ja) 2012-09-20
UY32514A (es) 2010-10-29
CN102481373A (zh) 2012-05-30
ZA201107022B (en) 2013-03-27
CN104127880A (zh) 2014-11-05
DOP2011000288A (es) 2012-01-15
WO2010108937A3 (en) 2010-11-25
TW201100104A (en) 2011-01-01
EP2411054A2 (en) 2012-02-01
SG174497A1 (en) 2011-10-28
MX2011010151A (es) 2011-12-14

Similar Documents

Publication Publication Date Title
CO6361953A2 (es) Fusiones y conjugados de fármaco
MX2010010776A (es) Fusiones y conjugados de farmaco.
MX2012003939A (es) Fusiones y conjugados de farmaco.
CY1124500T1 (el) Συνθεση που περιλαμβανει αντισωμα που δεσμευεται με περιοχη ii toy her2 και οξινες παραλλαγες αυτου
BR112015008311A2 (pt) conjugados fármaco-proteína
CL2013001279A1 (es) Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
UY31504A1 (es) Construcciones de union de antigenos
EA201890389A3 (ru) Композиции конъюгата xten и способы их получения
WO2013184938A3 (en) Fusion polypeptides comprising mucin-domain polypeptide linkers
BR112015012933A2 (pt) proteínas de ligação ao antígeno bcma
BR112014019611A2 (pt) agentes de ligação mica
MX2012000765A (es) Dominios variables sencillos de union de albumina anti-suero mejorados.
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
BR112012007523A2 (pt) moléculas de anticorpo anti-gcc e composições e métodos relacionados
BR112017022256A2 (pt) conjugados de anticorpo-droga sítio-específicos
WO2011086143A3 (en) Liver targeting domain antibodies
MA34025B1 (fr) Polypeptides se liant au bêta-a
MX2015012570A (es) Conjugacion de anticuerpo-farmaco especifica de sitio mediante glicoingenieria.
BR112014023415A2 (pt) moléculas que se ligam a ang2
EA201590412A1 (ru) Композиции антител и их применения
IL237345B (en) Antibody and drug conjugates (adc) that bind to 158p1d7 proteins, preparations containing them and their uses
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
BR112013013003A2 (pt) proteína de ligação de antígeno, e, composição farmacêutica
UY35854A (es) Métodos para la conjugación de oxima con polipéptidos ceto-modificados
IL243860A0 (en) Antibody-drug conjugates that bind to cd37 proteins, preparations containing them and their uses

Legal Events

Date Code Title Description
FG Application granted